| Kelly Ann Zbanic, DO | |
|
500 Medical Arts Bldg Ste 540, Kittanning, PA 16201-7137 | |
| (724) 543-4942 | |
| Not Available |
| Full Name | Kelly Ann Zbanic |
|---|---|
| Gender | Female |
| Speciality | General Surgery |
| Experience | 19 Years |
| Location | 500 Medical Arts Bldg Ste 540, Kittanning, Pennsylvania |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1275703209 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | OS017098 (Pennsylvania) | Secondary |
| 208600000X | Surgery | OS10314 (Florida) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Acmh Hospital | Kittanning, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Glade Run Medical Associates Inc | 3577696897 | 28 |
News Archive
The global market for cosmeceuticals (cosmetics offering health benefits) is growing nearly twice as fast as the overall cosmetics and toiletries market. However, in order to sustain such rapid growth, manufacturers and brand owners must fill a relentless demand for new ingredient concepts in a context of changing government regulations, market dynamics and cultural trends.
Foods being marketed to children in UK supermarkets are less healthy than those marketed to the general population according to researchers at the University of Hertfordshire, who question whether more guidelines may be needed in regulating food marketed to children.
Cortex Pharmaceuticals, Inc. announced that it has entered into an agreement with Biovail Laboratories International SRL in which Biovail acquired certain AMPAKINE compounds and the rights to the patent filing for respiratory depression and vaso-occlusive crises associated with sickle cell disease.
PositiveID Corporation announced today that it has filed a provisional patent application with the U.S. Patent and Trademark Office covering the interface between a radio frequency ("RF") powered resonant electromechanical drive and the fluids in the interstitial space of a patient for continuous detection of glucose levels in a patient. The interface employs a resonant electromechanical drive for mass sensing and RF communication of glucose levels.
A DNA-level biomarker (MGMT promoter methylation) can be used to help predict survival outcomes in patients with high-risk, low-grade gliomas, according to a new study conducted through the NRG Oncology/RTOG collaborative clinical trials group and led by scientists at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
› Verified 2 days ago
| Entity Name | Armstrong County Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568577724 PECOS PAC ID: 9335051663 Enrollment ID: O20031104000468 |
News Archive
The global market for cosmeceuticals (cosmetics offering health benefits) is growing nearly twice as fast as the overall cosmetics and toiletries market. However, in order to sustain such rapid growth, manufacturers and brand owners must fill a relentless demand for new ingredient concepts in a context of changing government regulations, market dynamics and cultural trends.
Foods being marketed to children in UK supermarkets are less healthy than those marketed to the general population according to researchers at the University of Hertfordshire, who question whether more guidelines may be needed in regulating food marketed to children.
Cortex Pharmaceuticals, Inc. announced that it has entered into an agreement with Biovail Laboratories International SRL in which Biovail acquired certain AMPAKINE compounds and the rights to the patent filing for respiratory depression and vaso-occlusive crises associated with sickle cell disease.
PositiveID Corporation announced today that it has filed a provisional patent application with the U.S. Patent and Trademark Office covering the interface between a radio frequency ("RF") powered resonant electromechanical drive and the fluids in the interstitial space of a patient for continuous detection of glucose levels in a patient. The interface employs a resonant electromechanical drive for mass sensing and RF communication of glucose levels.
A DNA-level biomarker (MGMT promoter methylation) can be used to help predict survival outcomes in patients with high-risk, low-grade gliomas, according to a new study conducted through the NRG Oncology/RTOG collaborative clinical trials group and led by scientists at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
› Verified 2 days ago
| Entity Name | Glade Run Medical Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881820850 PECOS PAC ID: 3577696897 Enrollment ID: O20100806000006 |
News Archive
The global market for cosmeceuticals (cosmetics offering health benefits) is growing nearly twice as fast as the overall cosmetics and toiletries market. However, in order to sustain such rapid growth, manufacturers and brand owners must fill a relentless demand for new ingredient concepts in a context of changing government regulations, market dynamics and cultural trends.
Foods being marketed to children in UK supermarkets are less healthy than those marketed to the general population according to researchers at the University of Hertfordshire, who question whether more guidelines may be needed in regulating food marketed to children.
Cortex Pharmaceuticals, Inc. announced that it has entered into an agreement with Biovail Laboratories International SRL in which Biovail acquired certain AMPAKINE compounds and the rights to the patent filing for respiratory depression and vaso-occlusive crises associated with sickle cell disease.
PositiveID Corporation announced today that it has filed a provisional patent application with the U.S. Patent and Trademark Office covering the interface between a radio frequency ("RF") powered resonant electromechanical drive and the fluids in the interstitial space of a patient for continuous detection of glucose levels in a patient. The interface employs a resonant electromechanical drive for mass sensing and RF communication of glucose levels.
A DNA-level biomarker (MGMT promoter methylation) can be used to help predict survival outcomes in patients with high-risk, low-grade gliomas, according to a new study conducted through the NRG Oncology/RTOG collaborative clinical trials group and led by scientists at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kelly Ann Zbanic, DO 25 Heckel Rd, Mc Kees Rocks, PA 15136-1651 Ph: (727) 710-3900 | Kelly Ann Zbanic, DO 500 Medical Arts Bldg Ste 540, Kittanning, PA 16201-7137 Ph: (724) 543-4942 |
News Archive
The global market for cosmeceuticals (cosmetics offering health benefits) is growing nearly twice as fast as the overall cosmetics and toiletries market. However, in order to sustain such rapid growth, manufacturers and brand owners must fill a relentless demand for new ingredient concepts in a context of changing government regulations, market dynamics and cultural trends.
Foods being marketed to children in UK supermarkets are less healthy than those marketed to the general population according to researchers at the University of Hertfordshire, who question whether more guidelines may be needed in regulating food marketed to children.
Cortex Pharmaceuticals, Inc. announced that it has entered into an agreement with Biovail Laboratories International SRL in which Biovail acquired certain AMPAKINE compounds and the rights to the patent filing for respiratory depression and vaso-occlusive crises associated with sickle cell disease.
PositiveID Corporation announced today that it has filed a provisional patent application with the U.S. Patent and Trademark Office covering the interface between a radio frequency ("RF") powered resonant electromechanical drive and the fluids in the interstitial space of a patient for continuous detection of glucose levels in a patient. The interface employs a resonant electromechanical drive for mass sensing and RF communication of glucose levels.
A DNA-level biomarker (MGMT promoter methylation) can be used to help predict survival outcomes in patients with high-risk, low-grade gliomas, according to a new study conducted through the NRG Oncology/RTOG collaborative clinical trials group and led by scientists at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
› Verified 2 days ago
Mr. Charles E Sloane, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 100 Parkview Dr, Ste 2, Kittanning, PA 16201 Phone: 724-645-3663 Fax: 724-545-6905 | |
Paul L Frederick, M.D. Surgery Medicare: Not Enrolled in Medicare Practice Location: 500 Medical Arts Bldg, Suite 510, Kittanning, PA 16201 Phone: 724-954-6115 Fax: 724-548-5683 | |
Dr. Ricky P. Clay Jr., M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 1 Nolte Dr, Kittanning, PA 16201 Phone: 724-543-8500 | |
Rebecca D Edmonds, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 1 Nolte Dr, Kittanning, PA 16201 Phone: 833-246-7662 Fax: 724-671-1706 | |
Mohamad Rassoul Abu-nuwar, MD Surgery Medicare: Medicare Enrolled Practice Location: 500 Medical Arts Bldg Ste 540, Kittanning, PA 16201 Phone: 724-543-4942 |